Study of DCC-2812 for advanced genitourinary cancers
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental pill called DCC-2812 for people with advanced kidney, bladder, or prostate cancer. The goal is to see if it is safe and if it might help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic kidney cancer, bladder cancer, or prostate cancer that is no longer responding to hormone therapy.
- You need to be able to swallow pills and take medicines by mouth.
- You should not have had any other cancer treatment or experimental drug within a certain time before starting this study drug.
- Your heart function must be in good shape, and you must not have had major surgery in the last 28 days.
- If you are able to have children, you must agree to use effective contraception and have a negative pregnancy test if female.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This study tests whether a new drug called AK146D1, alone or combined with another drug called AK112, can help treat advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if these drugs can shrink tumors and improve survival.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.